Literature DB >> 23974097

Tumor protein D52 represents a negative regulator of ATM protein levels.

Yuyan Chen1, Alvin Kamili, Jayne R Hardy, Guy E Groblewski, Kum Kum Khanna, Jennifer A Byrne.   

Abstract

Tumor protein D52 (TPD52) is a coiled-coil motif bearing hydrophilic polypeptide known to be overexpressed in cancers of diverse cellular origins. Increased TPD52 expression is associated with increased proliferation and invasive capacity in different cell types. Recent studies have reported a correlation between TPD52 transcript levels and G 2 chromosomal radiosensitivity in lymphocytes of women at risk of hereditary breast cancer, and that TPD52 knockdown significantly reduced the radiation sensitivity of multiple cancer cell lines. In this study, we investigated possible roles for TPD52 in DNA damage response, and found that increased TPD52 expression in breast cancer and TPD52-expressing BALB/c 3T3 cells compromised ATM-mediated cellular responses to DNA double-strand breaks induced by γ-ray irradiation, which was associated with downregulation of steady-state ATM protein, but not transcript levels, regardless of irradiation status. TPD52-expressing 3T3 cells also showed significantly increased radiation sensitivity compared with vector cells evaluated by clonogenic assays. Furthermore, direct interactions between exogenous and endogenous ATM and TPD52 were detected by GST pull-down and co-immunoprecipitation assays. We also identified the interaction domains involved in this binding as TPD52 residues 111-131, and ATM residues 1-245 and 772-1102. Taken together, our results suggest that TPD52 may represent a novel negative regulator of ATM protein levels.

Entities:  

Keywords:  ATM; DNA damage response; TPD52; cancer; protein-protein interaction

Mesh:

Substances:

Year:  2013        PMID: 23974097      PMCID: PMC3875682          DOI: 10.4161/cc.26146

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  69 in total

Review 1.  ATM protein kinase: the linchpin of cellular defenses to stress.

Authors:  Shahzad Bhatti; Sergei Kozlov; Ammad Ahmad Farooqi; Ali Naqi; Martin Lavin; Kum Kum Khanna
Journal:  Cell Mol Life Sci       Date:  2011-05-02       Impact factor: 9.261

2.  Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro.

Authors:  S Matsuoka; G Rotman; A Ogawa; Y Shiloh; K Tamai; S J Elledge
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-12       Impact factor: 11.205

3.  PrLZ protects prostate cancer cells from apoptosis induced by androgen deprivation via the activation of Stat3/Bcl-2 pathway.

Authors:  Dong Zhang; Dalin He; Yan Xue; Ruoxiang Wang; Kaijie Wu; Hongjun Xie; Jin Zeng; Xinyang Wang; Haiyen E Zhau; Leland W K Chung; Luke S Chang; Lei Li
Journal:  Cancer Res       Date:  2011-03-08       Impact factor: 12.701

4.  ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors.

Authors:  Chris T Williamson; Huong Muzik; Ali G Turhan; Alberto Zamò; Mark J O'Connor; D Gwyn Bebb; Susan P Lees-Miller
Journal:  Mol Cancer Ther       Date:  2010-02-02       Impact factor: 6.261

5.  Altered expression of DNA double-strand break detection and repair proteins in breast carcinomas.

Authors:  S Angèle; I Treilleux; A Brémond; P Tanière; J Hall
Journal:  Histopathology       Date:  2003-10       Impact factor: 5.087

6.  Defining aggressive prostate cancer using a 12-gene model.

Authors:  Tarek A Bismar; Francesca Demichelis; Alberto Riva; Robert Kim; Sooryanarayana Varambally; Le He; Jeff Kutok; Jonathan C Aster; Jeffery Tang; Rainer Kuefer; Matthias D Hofer; Phillip G Febbo; Arul M Chinnaiyan; Mark A Rubin
Journal:  Neoplasia       Date:  2006-01       Impact factor: 5.715

7.  Low levels of ATM in breast cancer patients with clinical radiosensitivity.

Authors:  Zhiming Fang; Sergei Kozlov; Michael J McKay; Rick Woods; Geoff Birrell; Carl N Sprung; Dédée F Murrell; Kiran Wangoo; Linda Teng; John H Kearsley; Martin F Lavin; Peter H Graham; Raymond A Clarke
Journal:  Genome Integr       Date:  2010-06-24

8.  Expression of phosphorylated histone H2AX in cultured cell lines following exposure to X-rays.

Authors:  S H MacPhail; J P Banáth; T Y Yu; E H M Chu; H Lambur; P L Olive
Journal:  Int J Radiat Biol       Date:  2003-05       Impact factor: 2.694

9.  ATMIN defines an NBS1-independent pathway of ATM signalling.

Authors:  Nnennaya Kanu; Axel Behrens
Journal:  EMBO J       Date:  2007-05-24       Impact factor: 11.598

10.  Tumor protein D52 expression and Ca2+-dependent phosphorylation modulates lysosomal membrane protein trafficking to the plasma membrane.

Authors:  Diana D H Thomas; Christina L Martin; Ning Weng; Jennifer A Byrne; Guy E Groblewski
Journal:  Am J Physiol Cell Physiol       Date:  2009-12-23       Impact factor: 4.249

View more
  11 in total

1.  TPD52 expression increases neutral lipid storage within cultured cells.

Authors:  Alvin Kamili; Nuruliza Roslan; Sarah Frost; Laurence C Cantrill; Dongwei Wang; Austin Della-Franca; Robert K Bright; Guy E Groblewski; Beate K Straub; Andrew J Hoy; Yuyan Chen; Jennifer A Byrne
Journal:  J Cell Sci       Date:  2015-07-16       Impact factor: 5.285

2.  Tumor protein D52-like 2 contributes to proliferation of breast cancer cells.

Authors:  Mei Yang; Xueyao Wang; Jiaoyuan Jia; Hongwen Gao; Peng Chen; Xianliang Sha; Shan Wu
Journal:  Cancer Biother Radiopharm       Date:  2015-01-28       Impact factor: 3.099

Review 3.  Tumor protein D52 (TPD52) and cancer-oncogene understudy or understudied oncogene?

Authors:  Jennifer A Byrne; Sarah Frost; Yuyan Chen; Robert K Bright
Journal:  Tumour Biol       Date:  2014-05-06

4.  Tumor-suppressive microRNA-34a inhibits breast cancer cell migration and invasion via targeting oncogenic TPD52.

Authors:  Guodong Li; Lei Yao; Jinning Zhang; Xinglong Li; Shuwei Dang; Kai Zeng; Yuhui Zhou; Feng Gao
Journal:  Tumour Biol       Date:  2015-12-17

Review 5.  Novel targets for ATM-deficient malignancies.

Authors:  Johannes Winkler; Kay Hofmann; Shuhua Chen
Journal:  Mol Cell Oncol       Date:  2014-08-13

Review 6.  The Emerging Role of DNA Damage in the Pathogenesis of the C9orf72 Repeat Expansion in Amyotrophic Lateral Sclerosis.

Authors:  Anna Konopka; Julie D Atkin
Journal:  Int J Mol Sci       Date:  2018-10-12       Impact factor: 5.923

7.  Delayed recruiting of TPD52 to lipid droplets - evidence for a "second wave" of lipid droplet-associated proteins that respond to altered lipid storage induced by Brefeldin A treatment.

Authors:  Yuyan Chen; Sarah Frost; Matloob Khushi; Laurence C Cantrill; Hong Yu; Jonathan W Arthur; Robert K Bright; Guy E Groblewski; Jennifer A Byrne
Journal:  Sci Rep       Date:  2019-07-05       Impact factor: 4.379

8.  Star-PAP regulates tumor protein D52 through modulating miR-449a/34a in breast cancer.

Authors:  Aizhu Duan; Lingmei Kong; Tao An; Hongyu Zhou; Chunlei Yu; Yan Li
Journal:  Biol Open       Date:  2019-11-06       Impact factor: 2.422

9.  Tumor Protein D52 (TPD52) Inhibits Growth and Metastasis in Renal Cell Carcinoma Cells Through the PI3K/Akt Signaling Pathway.

Authors:  Zhenhua Zhao; Hui Liu; Junqing Hou; Tieqiang Li; Xinyi Du; Xiaolei Zhao; Wenchao Xu; Weibo Xu; Junkai Chang
Journal:  Oncol Res       Date:  2016-11-08       Impact factor: 5.574

10.  Decreased TPD52 expression is associated with poor prognosis in primary hepatocellular carcinoma.

Authors:  Ying Wang; Chang-Long Chen; Qiu-Zhong Pan; Ying-Yuan Wu; Jing-Jing Zhao; Shan-Shan Jiang; Jie Chao; Xiao-Fei Zhang; Hong-Xia Zhang; Zi-Qi Zhou; Yan Tang; Xu-Qiong Huang; Jian-Hua Zhang; Jian-Chuan Xia
Journal:  Oncotarget       Date:  2016-02-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.